NCT06108648 Efficacy of Lavender Essential Oil Chest Wraps in Infants With Bronchiolitis
| NCT ID | NCT06108648 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University Hospital, Geneva |
| Condition | Bronchiolitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-12-07 |
| Primary Completion | 2026-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 400 participants in total. It began in 2023-12-07 with a primary completion date of 2026-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if lavender essential oil chest wraps relieve cough in infants with bronchiolitis compared to standard care. Furthermore, the researchers will evaluate if breathing difficulties, nighttime awakening and impact on parents will be improved by the lavender oil chest wraps. Infants will be randomized to receive standard care with the addition of lavender oil chest wraps or to receive standard care alone. The study will take place in two locations in Switzerland, at the Geneva University Hospital and the Fribourg Cantonal Hospital.
Eligibility Criteria
Inclusion criteria: * Bronchiolitis: clinical diagnosis based on the combination of respiratory distress (tachypnea, grunting, nasal flaring, retractions, and/or need for supplementary oxygen) and fine crackles sometimes accompanied by wheezing on auscultation. * Hospitalization. * Written informed consent. Exclusion criteria: * Patients with underlying diseases that impact respiratory or heart function (congenital heart disease, congenital malformation of the lung or airway system and severe chronic lung disease). * More than 3 episodes of bronchiolitis. * Critically ill infants who have an immediate need for intensive care unit (ICU) admission. * Respiratory deterioration needing Continuous positive airway pressure (CPAP) or transfer to ICU during study enrollment. * Atopic dermatitis, eczema or other skin lesions (particularly on the chest). * Oncologic disease. * Premature infants with mild bronchopulmonary dysplasia will not be excluded.
Contact & Investigator
Klara Posfay-Barbe, MD, PhD
STUDY DIRECTOR
Children's' Hospital, University Hospital of Geneva, Switzerland
Frequently Asked Questions
Who can join the NCT06108648 clinical trial?
This trial is open to participants of all sexes, up to 11 Months, studying Bronchiolitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06108648 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06108648 currently recruiting?
Yes, NCT06108648 is actively recruiting participants. Contact the research team at Fabiola.stollar@hcuge.ch for enrollment information.
Where is the NCT06108648 trial being conducted?
This trial is being conducted at Fribourg, Switzerland, Geneva, Switzerland.
Who is sponsoring the NCT06108648 clinical trial?
NCT06108648 is sponsored by University Hospital, Geneva. The principal investigator is Klara Posfay-Barbe, MD, PhD at Children's' Hospital, University Hospital of Geneva, Switzerland. The trial plans to enroll 400 participants.